keyword
MENU ▼
Read by QxMD icon Read
search

Sacubitril/valsartan

keyword
https://www.readbyqxmd.com/read/28330649/effect-of-sacubitril-valsartan-versus-enalapril-on-glycaemic-control-in-patients-with-heart-failure-and-diabetes-a-post-hoc-analysis-from-the-paradigm-hf-trial
#1
Jelena P Seferovic, Brian Claggett, Sara B Seidelmann, Ellen W Seely, Milton Packer, Michael R Zile, Jean L Rouleau, Karl Swedberg, Martin Lefkowitz, Victor C Shi, Akshay S Desai, John J V McMurray, Scott D Solomon
BACKGROUND: Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insulin sensitivity in obese hypertensive patients. We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA1c and time to first-time initiation of insulin or oral antihyperglycaemic drugs in patients with diabetes and HFrEF...
March 17, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28329188/let-us-not-forget-the-long-term-safety-concerns-of-sacubitril-valsartan-reply
#2
Milton Packer
No abstract text is available yet for this article.
March 22, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28329180/let-us-not-forget-the-long-term-safety-concerns-of-sacubitril-valsartan
#3
Cian P McCarthy, John W McEvoy
No abstract text is available yet for this article.
March 22, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28329132/corrigendum-to-sacubitril-valsartan-and-low-blood-pressure-in-heart-failure-with-reduced-ejection-fraction-eur-heart-j-2017-doi-10-1093-eurheartj-ehx014
#4
(no author information available yet)
No abstract text is available yet for this article.
February 28, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28326531/sacubitril-valsartan-for-treatment-of-chronic-heart-failure-with-reduced-ejection-fraction-can-all-patients-benefit-a-position-statement-paper-of-experts-of-the-heart-failure-working-group-of-the-polish-cardiac-society
#5
Ewa Straburzyńska-Migaj, Jadwiga Nessler, Marcin Gruchała, Karol Kamiński, Małgorzata Lelonek, Przemysław Leszek, Katarzyna Mizia-Stec, Piotr Rozentryt, Andrzej Gackowski, Adrian Gwizdała, Ewa A Jankowska, Piotr Ponikowski
No abstract text is available yet for this article.
2017: Kardiologia Polska
https://www.readbyqxmd.com/read/28318519/major-developments-in-the-2016-european-guidelines-for-heart-failure
#6
J C Trullàs, Á González-Franco
The European Society of Cardiology has recently published new guidelines on the diagnosis and treatment of acute and chronic heart failure (HF). This article aims to review these recommendations and their level of scientific evidence and to present the most innovative aspects. The most significant deviations from the 2012 edition are: 1) the introduction of the concept of HF with midrange LVEF (40-49%); 2) a new diagnostic algorithm for chronic HF, initially considering the clinical probability; 3) recommendations on preventing or delaying the apparition of HF; 4) indications for the use of the new sacubitril-valsartan compound, the first angiotensin receptor blocker and neprilysin inhibitor; 5) modification of indications for cardiac resynchronisation therapy; and 6) a new algorithm for a combined diagnostic and treatment strategy for acute HF based on the presence or absence of congestion and hypoperfusion...
March 15, 2017: Revista Clínica Española
https://www.readbyqxmd.com/read/28315356/the-effect-of-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-central-nervous-system-amyloid-%C3%AE-concentrations-and-clearance-in-the-cynomolgus-monkey
#7
Heidi A Schoenfeld, Tim West, Philip B Verghese, Mary Holubasch, Neeta Shenoy, David Kagan, Chiara Buono, Wei Zhou, Marc DeCristofaro, Julie Douville, Geoffrey G Goodrich, Keith Mansfield, Chandra Saravanan, Frederic Cumin, Randy L Webb, Randall J Bateman
Sacubitril/valsartan (LCZ696) is the first angiotensin receptor neprilysin inhibitor approved to reduce cardiovascular mortality and hospitalization in patients with heart failure with reduced ejection fraction. As neprilysin (NEP) is one of several enzymes known to degrade amyloid-β (Aβ), there is a theoretical risk of Aβ accumulation following long-term NEP inhibition. The primary objective of this study was to evaluate the potential effects of sacubitril/valsartan on central nervous system clearance of Aβ isoforms in cynomolgus monkeys using the sensitive Stable Isotope Labeling Kinetics (SILK™)-Aβ methodology...
March 15, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28292483/an-economic-evaluation-of-sacubitril-valsartan-for-heart-failure-patients-in-the-netherlands
#8
Simon van der Pol, Fabian Degener, Maarten J Postma, Pepijn Vemer
BACKGROUND: In September 2014, the PARADIGM-HF trial showed the heart failure drug combination sacubitril/valsartan to be superior to enalapril for patients with a reduced ejection fraction. OBJECTIVES: To determine the incremental cost-effectiveness of sacubitril/valsartan compared with enalapril in the Netherlands using the clinical data from the PARADIGM-HF trial. METHODS: To compare sacubitril/valsartan and enalapril in a cost-effectiveness study, a Markov model was developed using the effectiveness data from the PARADIGM-HF trial...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28285069/sacubitril-valsartan-the-newest-addition-to-the-toolbox-for-guideline-directed-medical-therapy-of-heart-failure
#9
REVIEW
Jo E Rodgers
Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker. As an inhibitor of neprilysin, an enzyme that degrade biologically active natriuretic peptides, this first-in-class therapy increases levels of circulating natriuretic peptides resulting in natriuretic, diuretic, and vasodilatory effects. In patients chronic New York Heart Association class II-IV heart failure with reduced ejection fraction, the PARADIGM-HF trial demonstrated that sacubitril/valsartan significantly reduced the primary endpoint of cardiovascular mortality and HF hospitalization compared to enalapril...
March 8, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28282683/-indications-and-clinical-implications-of-the-use-of-the-cardiac-markers-bnp-and-nt-probnp
#10
Andreas Luchner, Stephan von Haehling, Christian Holubarsch, Till Keller, Fabian Knebel, Christian Zugck, Ulrich Laufs
B-type natriuretic peptides are markers of myocardial wall stress. BNP or NT-proBNP are used for the differential diagnosis of acute dyspnoe where normal serum concentrations make a cardiac cause unlikely. New data show their importance for risk prediction in different stages of heart failure and in primary prevention. Natriuretic peptide guided therapy improves titration of heart failure medications. Compared to BNP, NT-proBNP is better suited during therapy with the new angiotensin-rezeptor-neprilysin-inhibitor Sacubitril/Valsartan...
March 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28281384/transport-properties-of-valsartan-sacubitril-and-its-active-metabolite-lbq657-as-determinants-of-disposition
#11
Imad Hanna, Natalya Alexander, Matthew H Crouthamel, John Davis, Adrienne Natrillo, Phi Tran, Arpine Vapurcuyan, Bing Zhu
1. The potential for drug-drug interactions of LCZ696 (a novel, crystalline complex comprising sacubitril and valsartan) was investigated in vitro. 2. Sacubitril was shown to be a highly permeable P-glycoprotein (P-gp) substrate and was hydrolyzed to the active anionic metabolite LBQ657 by human carboxylesterase 1 (CES1b and 1c). The multidrug resistance-associated protein 2 (MRP2) was shown to be capable of LBQ657 and valsartan transport that contributes to the elimination of either compound. 3. LBQ657 and valsartan were transported by OAT1, OAT3, OATP1B1 and OATP1B3, whereas no OAT- or OATP-mediated sacubitril transport was observed...
March 10, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28281174/potential-expanded-indications-for-neprilysin-inhibitors
#12
REVIEW
Elizabeth Riddell, Justin M Vader
PURPOSE OF REVIEW: The goal of this article is to review potential expanded indications for neprilysin inhibitors. This article reviews the rationale and design for ongoing and future trials of sacubitril/valsartan in cardiovascular and non-cardiovascular disease. RECENT FINDINGS: Randomized trial data are lacking for use of sacubitril/valsartan in acute heart failure and advanced heart failure. Mechanistic data from animal studies suggest a role for neprilysin inhibition in the treatment of post-myocardial infarction systolic dysfunction and heart failure with preserved ejection fraction...
April 2017: Current Heart Failure Reports
https://www.readbyqxmd.com/read/28275236/sacubitril-valsartan-in-the-treatment-of-arterial-hypertension-an-unaccomplished-promise
#13
Gema Ruiz-Hurtado, Luis M Ruilope
No abstract text is available yet for this article.
March 9, 2017: Hypertension Research: Official Journal of the Japanese Society of Hypertension
https://www.readbyqxmd.com/read/28266964/sacubitril-valsartan-for-heart-failure-from-devil-s-advocate-to-evidence-based-medicine
#14
Dragos Vinereanu
No abstract text is available yet for this article.
March 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28244205/what-proportion-of-patients-with-chronic-heart-failure-are-eligible-for-sacubitril-valsartan
#15
Pierpaolo Pellicori, Alessia Urbinati, Parin Shah, Alexandra MacNamara, Syed Kazmi, Riet Dierckx, Jufen Zhang, John G F Cleland, Andrew L Clark
AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril-valsartan in clinical practice. METHODS AND RESULTS: Between 2001 and 2014, 6131 patients consecutively referred to a community HF clinic with suspected HF were assessed. The criteria required to enter the randomized phase of PARADIGM-HF, including symptoms, NT-proBNP, and current treatment with or without target doses of ACE inhibitors or ARBs, were applied to identify the proportion of patients eligible for sacubitril-valsartan...
February 27, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28185709/heart-failure-guidelines-what-s-new
#16
REVIEW
Lampros Papadimitriou, Carine E Hamo, Javed Butler
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction...
January 11, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28178694/resolution-of-cheyne-stokes-respiration-after-treatment-of-heart-failure-with-sacubitril-valsartan-a-first-case-report
#17
Henrik Fox, Thomas Bitter, Dieter Horstkotte, Olaf Oldenburg
Sleep-disordered breathing (SDB) is highly prevalent in patients with heart failure (HF), and is known to be associated with a worse prognosis. The severity of central sleep apnea is thought to mirror cardiac dysfunction. The novel angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril has been shown to improve HF, but a relationship between treatment with ARNi and the severity of SDB has not yet been investigated. We report the case of a 71-year-old male with HF and SDB. Treatment with sacubitril/valsartan was associated with improved cardiac function, as shown by a reduction in the level of N-terminal prohormone of brain natriuretic peptide from 3,249 to 1,720 pg/mL, and an improvement in left-ventricular ejection fraction from 30 to 35%...
February 9, 2017: Cardiology
https://www.readbyqxmd.com/read/28176581/correction
#18
(no author information available yet)
There was an error in our CPD article Chronic heart failure part 2: treatment and management (11 January). On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction ≤35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016)...
February 8, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28158398/systolic-blood-pressure-cardiovascular-outcomes-and-efficacy-and-safety-of-sacubitril-valsartan-lcz696-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-results-from-paradigm-hf
#19
Michael Böhm, Robin Young, Pardeep S Jhund, Scott D Solomon, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Karl Swedberg, Michael R Zile, Milton Packer, John J V McMurray
No abstract text is available yet for this article.
February 1, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28133468/changing-the-treatment-of-heart-failure-with-reduced-ejection-fraction-clinical-use-of-sacubitril-valsartan-combination
#20
REVIEW
Edgardo Kaplinsky
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Neprilysin is an endopeptidase that breaks down several vasoactive peptides including natriuretic peptides (NPs), bradykinin, endothelin and angiotensin II (Ang-II)...
November 2016: Journal of Geriatric Cardiology: JGC
keyword
keyword
68706
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"